Evaluation of polydentate picolinic acid chelating ligands and an α-melanocyte-stimulating hormone derivative for targeted alpha therapy using ISOL-produced 225Ac.
Caterina F RamogidaAndrew K H RobertsonUna JermilovaChengcheng ZhangHua YangPeter KunzJens LassenIvica BratanovicVictoria BrownLily SouthcottCristina Rodríguez-RodríguezValery RadchenkoFrançois BénardChris OrvigPaul SchafferPublished in: EJNMMI radiopharmacy and chemistry (2019)
TRIUMF's ISOL facility is able to provide 225Ac suitable for preclinical screening of radiopharmaceutical compounds; [225Ac(octapa)]-, [225Ac(CHXoctapa)]-, and [225Ac(DOTA-CycMSH)] may be good candidates for further targeted alpha therapy studies.